tbuckley/cabot-search huggingface dataset:
Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma
Authors: Tyler J. Wildes, Adam Grippin, Kyle A. Dyson, Brandon M. Wummer, David J. Damiani, Rebecca S. Abraham, Catherine T. Flores, Duane A. Mitchell
Journal: Clinical Cancer Research (2018)

Purpose: Adoptive T-cell immunotherapy (ACT) has emerged as a viable therapeutic for peripheral and central nervous system (CNS) tumors. In peripheral cancers, optimal efficacy of ACT is reliant on dendritic cells (DCs) in the tumor microenvironment. However, the CNS is largely devoid of resident migratory DCs to function as antigen-presenting cells during immunotherapy. Herein, we demonstrate that cellular interactions between adoptively transferred tumor-reactive T cells and bone marrow-derived hematopoietic stem and progenitor cells (HSPCs) lead to the generation of potent intratumoral DCs within the CNS compartment.Experimental Design: We evaluated HSPC differentiation during ACT in vivo in glioma-bearing hosts and HSPC proliferation and differentiation in vitro using a T-cell coculture system. We utilized FACS, ELISAs, and gene expression profiling to study the phenotype and function of HSPC-derived cells ex vivo and in vivo To demonstrate the impact of HSPC differentiation and function on antitumor efficacy, we performed survival experiments.Results: Transfer of HSPCs with concomitant ACT led to the production of activated CD86+CD11c+MHCII+ cells consistent with DC phenotype and function within the brain tumor microenvironment. These intratumoral DCs largely supplanted abundant host myeloid-derived suppressor cells. We determined that during ACT, HSPC-derived cells in gliomas rely on T-cell-released IFNγ to differentiate into DCs, activate T cells, and reject intracranial tumors.Conclusions: Our data support the use of HSPCs as a novel cellular therapy. Although DC vaccines induce robust immune responses in the periphery, our data demonstrate that HSPC transfer uniquely generates intratumoral DCs that potentiate T-cell responses and promote glioma rejection in situClin Cancer Res; 24(16); 3955-66. ©2018 AACR.
A FEASIBILITY STUDY OF PATIENT AND CLINICIAN ACCEPTABILITY OF ACETIC-ACID CHROMOENDOSCOPY FOR BARRETT'S SURVEILLANCE: ABBA
Authors: G Longcroft-Wheaton, C Fogg, A Dewey, J DeCaestecker, H Barr, P Basford, A Li, S Green, C Gordon, B Higgins, M Mccord, J Jankowski, P Bhandari
Journal: Endoscopy (2018)
African Americans Are Less Likely to Receive Care by a Cardiologist During an Intensive Care Unit Admission for Heart Failure
Authors: Khadijah Breathett, Wenhui G Liu, Larry A Allen, Stacie L Daugherty, Irene V Blair, Jacqueline Jones, Gary K Grunwald, Marc Moss, Tyree H Kiser, Ellen Burnham, R William Vandivier, Brendan J Clark, Eldrin F Lewis, Sula Mazimba, Catherine Battaglia, P Michael Ho, Pamela N Peterson
Journal: JACC Heart Failure (2018)
P361Histone citrullination of neutrophil extracellular traps is a novel biomarker and target to inhibit progression of abdominal aortic aneurysms
Authors: W Eilenberg, B Zagrapan, L Martelanz, M T Grasl, A Potolidis, P Nawrozi, P Kirchweger, I Huk, C Neumayer, C Brostjan
Journal: Cardiovascular Research (2018)
Future Directions for Breast Reconstruction on the 20th Anniversary of the Women’s Health and Cancer Rights Act
Authors: Anaeze C. Offodile, Clara Nan-hi Lee
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis
Authors: M.B. Ferret, J. Pineda, J.L.C. Panero, M. Rodríguez, R.M. Morillas, J.M. Pascasio, A. Rivero, B. Mcnabb, G. Zhang, G. Camus, L. Stamm, D. Brainard, M. Subramanian, J.A. Carrión, R.J. Andrade, L.E.M. Amado, J. Turnés, S. Lens, M. Casado, R. Esteban
Journal: Journal of Hepatology (2018)
Which Patients With Cervical Squamous Cell Carcinoma Might Benefit From Neoadjuvant Chemotherapy?
Authors: Omar Mahmoud, Mark H. Einstein
Journal: Journal of Clinical Oncology (2018)

The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice. A 55-year-old postmenopausal woman, gravida 5 para 5, with past medical history significant for hypertension, presented to the emergency department with profuse vaginal bleeding and a hemoglobin level of 9 g/dL. The biopsy from an irregular 6-cm cervical mass was consistent with moderately differentiated cervical squamous cell carcinoma. The physical examination did not reveal vaginal or parametrial extension of the tumor. Pelvic magnetic resonance imaging disclosed the known carcinoma, as well as a 9.2 × 7.7 × 6.7 cm anterior uterine fibroid (Fig 1). A staging positron emission tomography scan was negative for metastatic disease. After blood transfusion and vaginal packing, the patient was referred to discuss the immediate management of her newly diagnosed bleeding bulky cervical cancer. In the absence of parametrial or vaginal extension and in the absence of lymph node metastasis (both on clinical examination and imaging), she was classified as having International Federation of Gynecology and Obstetrics stage IB2 disease.
Mutant allele-specific imbalance in patients with metastatic colorectal cancer.
Authors: Nirit Yarom, Miriam Birenboim, Adi Binder-Gallimidi, Ekaterina Hanovich, Avishay Sella
Journal: Journal of Clinical Oncology (2018)

706 Background: Patients with colorectal cancer(CRC) harboring RAS mutations do not respond to antiepidermal growth factor receptor (anti-EGFR) therapy. Next generation sequencing (NGS) identifies and quantifies mutant and wild type alleles as seen on the sequencing electropherograms. RAS mutant allele-specific imbalance (MASI) occurs when the mutant allele peak is higher than the wild type one. The aims of this study were to verify the rate and tissue distribution of RAS MASI as well as its clinical relevance. Methods: Results of NGS study of patients with metastatic colorectal cancer were collected retrospectively. The clinical charts of patients with RAS mutations were reviewed by the investigators who were blinded to the MASI results. Results: Between August 2014 and Jan 2016, 26 out of 52 (50%)patients tested, were found to harbor RAS mutations. Among them, 11 patients were detected with KRAS MASI(42.3%) Table 1 shows the different characteristics. 6 out of 11 patients presented with synchronous metastatic disease. This correlated with a statistically significant difference in the mean disease free survival that was 9 months in the KRAS MASI group compared with 27.5 months in the non MASI group. A few patients had more than one mutation. ie KRAS Ex2- G12D, 62.3%, PKI3CA Ex9-E545K, 24.6%, Ex20-H1047Y, 0.6% in the MASI group and KRAS Ex2-G12C+G12V - 10.85%, KRAS Ex4-A146T - 10.3%, NRAS gene Ex2-G12D - 1.1%, in non MASI group. Patients in the MASI group had a different clinical profile. (See Table 1) The overall survival of patients was calculated from diagnosis of metastatic disease, till death, 24 months-this was not significantly nor statistically different amongst groups. Conclusions: With the caveat of a small study and a retrospective analysis we showed that patients with MASI have worse characteristics that were translated to a significant shorter disease free survival. OS was not different amongst the groups. [Table: see text]
Speaking With Your Hands—The History of the Manicure
Authors: John P. Tsatalis, Ali Rajabi-Estarabadi, Antonella Tosti
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Treatment with the Adra2a antagonist, Yohimbine, reduces fibrosis progression and liver inflammation in a NASH fibrosis rat
Authors: H. Jones, S.E. Andreasen, A. Habtesion, P.L. Eriksen, N. Davies, R. Jalan, K.L. Thomsen, R. Mookerjee
Journal: Journal of Hepatology (2018)
Redefining Informed Consent as Part of Consent Training in Pediatrics
Authors: Rachel Jones, Behzad Talebian, Vinci Jones
Journal: JAMA Pediatrics (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Graphene oxide sensitizes cancer cells to chemotherapeutics by inducing early autophagy events, promoting nuclear trafficking and necrosis
Authors: Kuan-Chen Lin, Mei-Wei Lin, Mu-Nung Hsu, Guan Yu-Chen, Yu-Chan Chao, Hsing-Yu Tuan, Chi-Shiun Chiang, Yu-Chen Hu
Journal: Theranostics (2018)

Rationale: Cisplatin (CDDP) is a broad-spectrum anticancer drug but chemoresistance to CDDP impedes its wide use for cancer therapy. Autophagy is an event occurring in the cytoplasm and cytoplasmic LC3 puncta formation is a hallmark of autophagy. Graphene oxide (GO) is a nanomaterial that provokes autophagy in CT26 colon cancer cells and confers antitumor effects. Here we aimed to evaluate whether combined use of GO with CDDP (GO/CDDP) overcomes chemoresistance in different cancer cells and uncover the underlying mechanism. Methods: We treated different cancer cells with GO/CDDP and evaluated the cytotoxicity, death mechanism, autophagy induction and nuclear entry of CDDP. We further knocked down genes essential for autophagic flux and deciphered which step is critical to nuclear import and cell death. Finally, we performed immunoprecipitation, mass spectrometry and immunofluorescence labeling to evaluate the association of LC3 and CDDP. Results: We uncovered that combination of GO and CDDP (GO/CDDP) promoted the killing of not only CT26 cells, but also ovarian, cervical and prostate cancer cells. In the highly chemosensitized Skov-3 cells, GO/CDDP significantly enhanced concurrent nuclear import of CDDP and autophagy marker LC3 and elevated cell necrosis, which required autophagy initiation and progression but did not necessitate late autophagy events (e.g., autophagosome completion and autolysosome formation). The GO/CDDP-elicited nuclear trafficking and cell death also required importin α/β, and LC3 also co-migrated with CDDP and histone H1/H4 into the nucleus. In particular, GO/CDDP triggered histone H4 acetylation in the nucleus, which could decondense the chromosome and enable CDDP to more effectively access chromosomal DNA to trigger cell death. Conclusion: These findings shed light on the mechanisms of GO/CDDP-induced chemosensitization and implicate the potential applications of GO/CDDP to treat multiple cancers.
Activation of coagulation and endothelium with concurrent impairment of anticoagulant mechanisms in patients with typhoid fever
Authors: Hanna K. de Jong, Chris M. Parry, Thomas W. van der Vaart, Liesbeth M. Kager, Stannie J. van den Ende, Rapeephan R. Maude, Lalith Wijedoru, Aniruddha Ghose, Mohammed U. Hassan, Mohammed A. Hossain, Arjan M. Dondorp, Steve Baker, M. Abul Faiz, Joost C.M. Meijers, W. Joost Wiersinga
Journal: Journal of Infection (2018)

ObjectivesTyphoid fever caused by Salmonella Typhi remains a major burden worldwide. Gastrointestinal bleeding can be seen in up to 10 percent of patients and may be fatal. The coagulopathy, which may be the driver of this severe complication in patients with typhoid fever, however is ill defined. The aim of this study was to evaluate the activation of coagulation, anticoagulation, and fibrinolysis in patients with acute typhoid fever.MethodsParameters of coagulation and fibrinolysis were measured in 28 hospitalized patients with culture-confirmed or PCR-confirmed typhoid fever and compared to 38 age- and sex-matched healthy volunteers.ResultsPatients demonstrated activation of the coagulation system, as reflected by elevated in vitro thrombin generation and high plasma levels of fibrinogen, D-dimer and prothrombin fragment F1 + 2 in concert with consumption of coagulation factors resulting in a prolonged prothrombin-time and activated-partial-thromboplastin-time. Concurrently, the anticoagulant proteins, protein C and antithrombin, were significantly lower in comparison to healthy controls. Patients also demonstrated evidence of activation and inhibition of fibrinolysis and a marked activation of endothelial cells. The extent of coagulation activation was associated with the course of the disease, repeated testing during convalescence showed a return toward normal values.ConclusionsActivation of coagulation is an important clinical feature of typhoid fever and is associated with severity of disease.
Prospective evaluation of serum gamma-glutamyl transferase (GGT) for the prediction of disease progression in a randomized trial of patients with primary sclerosing cholangitis (PSC)
Authors: C. Levy, M. Shiffman, H. Janssen, A. Montano-Loza, S. Caldwell, V. Luketic, D. Ding, B. Mccolgan, R. Myers, B. Eksteen, R.W.G. Chapman, M.P. Manns, Z. Goodman, C. Bowlus, A. Muir, G. Hirschfield
Journal: Journal of Hepatology (2018)
TCTAP A-004 A Prospective, Multi-center Registry to Assess the Novel Sirolimus-eluting Stent with Unique Fusion Coating for Coronary Revascularization in Real World Population: The en-ABL e-registry
Authors: Sameer Dani, Devang Desai, Rashmit Pandya, Apurva Vasavada, PrathapKumar Pillai, Nirav Bhalani, Arvind Sharma, Chirag Sheth, Rutvik Trivedi, Dinesh Shah
Journal: Journal of the American College of Cardiology (2018)
Serum 25-hydroxyvitamin D levels and risk of lung cancer and histologic types: a Mendelian randomisation analysis of the HUNT study
Authors: Yi-Qian Sun, Ben M. Brumpton, Carolina Bonilla, Sarah J. Lewis, Stephen Burgess, Frank Skorpen, Yue Chen, Tom I.L. Nilsen, Pål Richard Romundstad, Xiao-Mei Mai
Journal: European Respiratory Journal (2018)

We aimed to investigate potential causal associations between serum 25-hydroxyvitamin D (25(OH)D) levels and incidence of lung cancer overall and histologic types. We performed a Mendelian randomisation analysis using a prospective cohort study in Norway, including 54 580 individuals and 676 incident lung cancer cases. A 25(OH)D allele score was generated based on the vitamin D-increasing alleles rs2282679, rs12785878 and rs10741657. Hazard ratios with 95% confidence intervals for incidence of lung cancer and histologic types were estimated in relation to the allele score. The inverse-variance weighted method using summarised data of individual single nucleotide polymorphisms was applied to calculate the Mendelian randomisation estimates. The allele score accounted for 3.4% of the variation in serum 25(OH)D levels. There was no association between the allele score and lung cancer incidence overall, with HR 0.99 (95% CI 0.93–1.06) per allele score. A 25 nmol·L −1 increase in genetically determined 25(OH)D level was not associated with the incidence of lung cancer overall (Mendelian randomisation estimate HR 0.96, 95% CI 0.54–1.69) or any histologic type. Mendelian randomisation analysis did not suggest a causal association between 25(OH)D levels and risk of lung cancer overall or histologic types in this population-based cohort study.
Advances in Automation Technologies for Lower Extremity Neurorehabilitation: A Review and Future Challenges
Authors: Wenhao Deng, Ioannis Papavasileiou, Zhi Qiao, Wenlong Zhang, Kam-Yiu Lam, Song Han
Journal: IEEE Reviews in Biomedical Engineering (2018)

The world is experiencing an unprecedented, enduring, and pervasive aging process. With more people who need walking assistance, the demand for lower extremity gait rehabilitation has increased rapidly over the years. The current clinical gait rehabilitative training requires heavy involvement of both medical doctors and physical therapists, and thus, are labor intensive, subjective, and expensive. To address these problems, advanced automation techniques, especially along with the proliferation of smart sensing and actuation devices and big data analytics platforms, have been introduced into this field to make the gait rehabilitation convenient, efficient, and personalized. This survey paper provides a comprehensive review on recent technological advances in wearable sensors, biofeedback devices, and assistive robots. Empowered by the emerging networking and computing technologies in the big data era, these devices are being interconnected into smart and connected rehabilitation systems to provide nonintrusive and continuous monitoring of physical and neurological conditions of the patients, perform complex gait analysis and diagnosis, and allow real-time decision making, biofeedback, and control of assistive robots. For each technology category, a detailed comparison among the existing solutions is provided. A thorough discussion is also presented on remaining open problems and future directions to further improve the safety, efficiency, and usability of the technologies.
Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Authors: Rachel A. Burga, Eric Yvon, Elizabeth Chorvinsky, Rohan Fernandes, C. Russell Y. Cruz, Catherine M. Bollard
Journal: Clinical Cancer Research (2019)

Abstract Purpose: The ability of natural killer (NK) cells to lyse allogeneic targets, without the need for explicit matching or priming, makes them an attractive platform for cell-based immunotherapy. Umbilical cord blood is a practical source for generating banks of such third-party NK cells for “off-the-shelf” cell therapy applications. NK cells are highly cytolytic, and their potent antitumor effects can be rapidly triggered by a lack of HLA expression on interacting target cells, as is the case for a majority of solid tumors, including neuroblastoma. Neuroblastoma is a leading cause of pediatric cancer–related deaths and an ideal candidate for NK-cell therapy. However, the antitumor efficacy of NK cells is limited by immunosuppressive cytokines in the tumor microenvironment, such as TGFβ, which impair NK cell function and survival. Experimental Design: To overcome this, we genetically modified NK cells to express variant TGFβ receptors, which couple a mutant TGFβ dominant-negative receptor to NK-specific activating domains. We hypothesized that with these engineered receptors, inhibitory TGFβ signals are effectively converted to activating signals. Results: Modified NK cells exhibited higher cytotoxic activity against neuroblastoma in a TGFβ-rich environment in vitro and superior progression-free survival in vivo, as compared with their unmodified controls. Conclusions: Our results support the development of “off-the-shelf” gene-modified NK cells, that overcome TGFβ-mediated immune evasion, in patients with neuroblastoma and other TGFβ-secreting malignancies.
The combination of acute-on-chronic liver failure (ACLF) as defined by EASL-CLIF consortium definition and MELD can predict post-transplant survival in patients with ACLF
Authors: U. Agbim, A. Sharma, S. Karri, J. Vanatta, H. Gonzalez, S. Nair, J. Eason, B. Maliakkal, S. Satapathy
Journal: Journal of Hepatology (2018)
QOF “unlikely” to disappear in England but could be slimmed down
Authors: Gareth Iacobucci
Journal: BMJ (2018)

The Quality and Outcomes Framework (QOF) is “unlikely” to disappear in England but could be drastically slimmed down, the vice chair of the Royal College of GPs has said.

NHS England and the BMA’s General Practitioners Committee (GPC) have been engaged in a major ongoing review of QOF, to examine whether to retain, reshape, or phase out the incentive system. Changes to GPs’ contracts were initially expected to be introduced this year, but could now occur in 2019-20 as no …